CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

Overview of attention for article published in Proceedings of the National Academy of Sciences of the United States of America, August 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

news: 1 news outlet
twitter: 8 X users

patent: 12 patents
f1000: 1 research highlight platform

Readers on

mendeley: 198 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 10 X posts from 8 X users, with an upper bound of 53,682 followers.

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. https://t.co/NzgxuDiMlF

RT @ARD_BMJ: CBP/p300 bromodomain inhibitor reduces #Th17 responses in #psoriatic #arthritis #pnas #epigenetics http://t.co/KLwKEgvsBH

RT @humanimmunenews: CBP30, a Selective CBP/p300 Bromodomain Inhibitor, Suppresses Human Th17 Responses @PNASNews http://t.co/PHokpzuedM

CBP30, a Selective CBP/p300 Bromodomain Inhibitor, Suppresses Human Th17 Responses @PNASNews http://t.co/PHokpzuedM

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 6 additional X posts.